Levels of hypoxia-inducible factor-1α independently predict prognosis in patients with lymph node negative breast carcinoma

Cancer

Volumn 97, Issue 6, 2003, Pages 1573-1581

  Bos, Reinhard ^a   Van der Groep, Petra ^a   Greijer, Astrid E ^a   Shvarts, Avi ^a   Meijer, Sybren ^a   Pinedo, Herbert M ^a   Semenza, Gregg L ^b   Van Diest, Paul J ^a   Van der Wall, Elsken ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma; Estrogen receptor; HER 2 neu; Hypoxia inducible factor 1 ; Mitotic activity index; Progesterone receptor; Prognosis

Indexed keywords

EOSIN; ESTROGEN RECEPTOR; HEMATOXYLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL DECISION MAKING; MITOSIS INDEX; ONCOGENE NEU; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL TIME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HELIX-LOOP-HELIX MOTIFS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037443587     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11246     Document Type: Article

References (39)

1. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst. 2001;93:266-276.
2. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol. 2000;88: 1474-1480.
3. Semenza GL. Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol. 2000;35:71-103.
4. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor-1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular 02 tension. Proc Natl Acad Sci USA. 1995;92:5510-5514.
5. Yu AY, Frid MG, Shimoda LA, Wiener CM, Stenmark K, Semenza GL. Temporal, spatial, and oxygen-regulated expression of hypoxia-inducible factor-1 in the lung. Am J Physiol 1998;275:L818-L826.
6. Huang LE, Arany Z, Livingston DM, Bunn HF. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996;271:32253-32259.
7. 2 tension. Am J Physiol. 1996;271:C1172- C1180.
8. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000;14:34-44.
9. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399:271-275.
10. Semenza GL. Regulation of mammalian 02 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol. 1999;15: 551-578.
11. Ratcliffe PJ, O'Rourke JF, Maxwell PH, Pugh CW. Oxygen sensing, hypoxia-inducible factor-1 and the regulation of mammalian gene expression. J Exp Biol. 1998;201:1153-1162.
12. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc Natl Acad Sci USA. 1997;94:8104-8109.
13. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84: 1875-1887.
14. De Jong JS, van Diest PJ, Baak JP. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology. 2000;36:306-312.
15. Harris AL. Antiangiogenesis for cancer therapy. Lancet. 1997;349(Suppl 2):SII13-SII15.
16. Linderholm B, Tavelin B, Grankvist K, Henriksson R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J Clin Oncol. 1998;16:3121- 3128.
17. West CM, Cooper RA, Loncaster JA, Wilks DP, Bromley M. Tumor vascularity: a histological measure of angiogenesis and hypoxia. Cancer Res. 2001;61:2907-2910.
18. Stubbs M, McSheehy PM, Griffiths JR, Bashford CL. Causes and consequences of tumour acidity and implications for treatment. Mol Med Today. 2000;6:15-19.
19. Bos R, Zhong H, Hanrahan CF, et al. Levels of hypoxiainducible factor-1alpha during breast carcinogenesis. J Natl Cancer Inst. 2001;93:309-314.
20. Chia SK, Wykoff CC, Watson PH, et al. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001;19:3660-3668.
21. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: novel mechanism for hif-1-mediated vascular endothelial growth factor expression. Mol Cell Biol. 2001;21:3995-4004.
22. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in earlystage invasive cervical cancer. Cancer Res. 2000;60:4693-4696.
23. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res. 2001;61:2911-2916.
24. Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer. 2001; 92:165-171.
25. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer. 2001;85:881-890.
26. Volm M, Koomagi R. Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. Anticancer Res. 2000;20:1527-1533.
27. Beasley NJ, Leek R, Alam M, et al. Hypoxia-inducible factors HIF-1alpha and HIF-2alpha in head and neck cancer: relationship to tumor biology and treatment outcome in surgically resected patients. Cancer Res. 2002;62:2493-2497.
28. Nakayama K, Kanzaki A, Hata K, et al. Hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression in human ovarian carcinoma. Cancer Lett. 2002;176:215-223.
29. Page DL. Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol. 1991;15: 334-349.
30. Jannink I, van Diest PI, Baak JP. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995;26:1086-1092.
31. World Health Organization. Histological typing of breast tumors. Tumori. 1982;68:181-198.
32. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer; experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
33. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors, 5th edition. New York: Wiley-Liss, 1997.
34. Bos R, van der Hoeven JJM, van der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-387.
35. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59:5830-5835.
36. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
37. Bosman FT, de Goeij AF, Rousch M. Quality control in immunocytochemistry: experiences with the oestrogen receptor assay. J Clin Pathol. 1992;45:120-124.
38. van Diest PJ, Baak JP, Matze-Cok P, et al. Reproducibility of mitosis counting in 2469 breast cancer specimens: results from the Multicenter Morphometric Mammary Carcinoma Project. Hum Pathol. 1992;23:603-607.
39. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist. 2000;5(Suppl 1):37-44.